ACB
Price
$4.91
Change
+$0.08 (+1.66%)
Updated
Sep 5 closing price
Capitalization
276.48M
61 days until earnings call
CRON
Price
$2.50
Change
-$0.00 (-0.00%)
Updated
Sep 5 closing price
Capitalization
966.06M
60 days until earnings call
Interact to see
Advertisement

ACB vs CRON

Header iconACB vs CRON Comparison
Open Charts ACB vs CRONBanner chart's image
Aurora Cannabis
Price$4.91
Change+$0.08 (+1.66%)
Volume$819.6K
Capitalization276.48M
Cronos Group
Price$2.50
Change-$0.00 (-0.00%)
Volume$1.97M
Capitalization966.06M
ACB vs CRON Comparison Chart in %
Loading...
ACB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CRON
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ACB vs. CRON commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACB is a Hold and CRON is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (ACB: $4.91 vs. CRON: $2.50)
Brand notoriety: ACB: Notable vs. CRON: Not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ACB: 57% vs. CRON: 73%
Market capitalization -- ACB: $276.48M vs. CRON: $966.06M
ACB [@Pharmaceuticals: Generic] is valued at $276.48M. CRON’s [@Pharmaceuticals: Generic] market capitalization is $966.06M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $67.95B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.93B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACB’s FA Score shows that 0 FA rating(s) are green whileCRON’s FA Score has 1 green FA rating(s).

  • ACB’s FA Score: 0 green, 5 red.
  • CRON’s FA Score: 1 green, 4 red.
According to our system of comparison, CRON is a better buy in the long-term than ACB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACB’s TA Score shows that 7 TA indicator(s) are bullish while CRON’s TA Score has 3 bullish TA indicator(s).

  • ACB’s TA Score: 7 bullish, 4 bearish.
  • CRON’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, ACB is a better buy in the short-term than CRON.

Price Growth

ACB (@Pharmaceuticals: Generic) experienced а -9.41% price change this week, while CRON (@Pharmaceuticals: Generic) price change was -3.85% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.08%. For the same industry, the average monthly price growth was +12.00%, and the average quarterly price growth was +86.48%.

Reported Earning Dates

ACB is expected to report earnings on Nov 06, 2025.

CRON is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+0.08% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRON($966M) has a higher market cap than ACB($276M). CRON has higher P/E ratio than ACB: CRON (50.00) vs ACB (21.12). CRON YTD gains are higher at: 23.762 vs. ACB (15.529). ACB has higher annual earnings (EBITDA): 26.6M vs. CRON (-25.58M). CRON has more cash in the bank: 834M vs. ACB (140M). CRON has less debt than ACB: CRON (2.01M) vs ACB (102M). ACB has higher revenues than CRON: ACB (358M) vs CRON (130M).
ACBCRONACB / CRON
Capitalization276M966M29%
EBITDA26.6M-25.58M-104%
Gain YTD15.52923.76265%
P/E Ratio21.1250.0042%
Revenue358M130M275%
Total Cash140M834M17%
Total Debt102M2.01M5,072%
FUNDAMENTALS RATINGS
ACB vs CRON: Fundamental Ratings
ACB
CRON
OUTLOOK RATING
1..100
2214
VALUATION
overvalued / fair valued / undervalued
1..100
58
Fair valued
68
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9391
PRICE GROWTH RATING
1..100
6141
P/E GROWTH RATING
1..100
826
SEASONALITY SCORE
1..100
7550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ACB's Valuation (58) in the Pharmaceuticals Other industry is in the same range as CRON (68). This means that ACB’s stock grew similarly to CRON’s over the last 12 months.

ACB's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as CRON (100). This means that ACB’s stock grew similarly to CRON’s over the last 12 months.

CRON's SMR Rating (91) in the Pharmaceuticals Other industry is in the same range as ACB (93). This means that CRON’s stock grew similarly to ACB’s over the last 12 months.

CRON's Price Growth Rating (41) in the Pharmaceuticals Other industry is in the same range as ACB (61). This means that CRON’s stock grew similarly to ACB’s over the last 12 months.

CRON's P/E Growth Rating (6) in the Pharmaceuticals Other industry is significantly better than the same rating for ACB (82). This means that CRON’s stock grew significantly faster than ACB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACBCRON
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
86%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
78%
Momentum
ODDS (%)
Bullish Trend 1 day ago
74%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
85%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
76%
Advances
ODDS (%)
Bullish Trend 10 days ago
78%
Bullish Trend 10 days ago
71%
Declines
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 12 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
88%
Aroon
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 4 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
ACB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CRON
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AAVXF88.9011.90
+15.45%
Abivax SA
NPSNY65.541.67
+2.61%
Naspers Ltd.
CFXTF0.20N/A
N/A
Conifex Timber Inc.
CSBTF32.00N/A
N/A
Kuros Bioscience Ltd.
RROTF2.32N/A
N/A
Roots Corporation

ACB and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACB has been loosely correlated with CGC. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if ACB jumps, then CGC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACB
1D Price
Change %
ACB100%
+1.66%
CGC - ACB
64%
Loosely correlated
+5.80%
OGI - ACB
63%
Loosely correlated
+2.48%
CRON - ACB
54%
Loosely correlated
N/A
TLRY - ACB
53%
Loosely correlated
+3.48%
PAHC - ACB
31%
Poorly correlated
+0.97%
More

CRON and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRON has been loosely correlated with TLRY. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if CRON jumps, then TLRY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRON
1D Price
Change %
CRON100%
N/A
TLRY - CRON
61%
Loosely correlated
+3.48%
OGI - CRON
58%
Loosely correlated
+2.48%
CGC - CRON
57%
Loosely correlated
+5.80%
ACB - CRON
55%
Loosely correlated
+1.66%
EBS - CRON
29%
Poorly correlated
-0.66%
More